Monash University

Monash University2019-10-02T02:14:57+00:00

Greg Moseley

Email: greg.moseley@monash.edu
T: +61  3  9905 1036
F: +61  3  9902 9222
Web: www.med.monash.edu.au/microbiology/
www.monash.edu/discovery-institute
Twitter: @gregwmoseley, @moseley_lab
Facebook: www.facebook.com/Moseley-Lab-222691648443326

Viral disease progression is critically dependent on the formation of specific interaction networks between viral proteins and host cell factors, which enable viral subversion of important processes such as antiviral immunity and cell survival.

Research in our laboratory seeks to elucidate these interactions at the molecular level, particularly interactions involved in immune evasion, and to understand their functions in diseases caused by highly lethal human viruses, including rhabdoviruses (e.g. rabies virus, Australian bat lyssavirus), paramyxoviruses (e.g. Nipah, Hendra, measles) and filoviruses (e.g. Ebola), as well as a number of agriculturally significant and potentially zoonotic animal viruses.

The overarching aim of the research is to identify novel targets and strategies for the development of new vaccines and therapeutics for currently incurable viral diseases.

Department of Microbiology, Biomedicine Discovery Institute

Monash University
19 Innovation Walk (Bldg 76)
Clayton Campus, Victoria 3800
Australia

Dr Rommel Mathias

BiomedSci Hons (The University of Melbourne) Department of Biochemistry and Molecular Biology.
PhD (The University of Melbourne) Department of Biochemistry and Molecular Biology.
Head, Viral Pathogenesis and Host Cellular Defense Laboratory (Monash University), Department of Microbiology, and Department of Biochemistry and Molecular Biology.

Email: rommel.mathias@monash.edu
Phone: +613 9902 9322
Web: www.med.monash.edu.au/microbiology/research/mathias.html

HCMV is a herpesvirus that infects over 60% of the adult population. It is a significant cause of morbidity and mortality in immuno-compromised individuals, such as transplant recipients. Additionally, intrauterine transmission during pregnancy can cause permanent hearing loss, vision impairment, and mental retardation to the foetus. A robust and effective vaccine is not currently available, and discovery of new antivirals is urgently required. The process by which infectious virus is packaged and released is not well understood, and this presents a novel molecular axis to develop antiviral therapeutics. Research in our laboratory uses a multidisciplinary approach to better understand host defence mechanisms, and reveal cellular pathways that are hijacked by HCMV for virion maturation and secondary envelopment. We work at the interface between cell biology, virology, microscopy, and quantitative proteomics, to identify host and viral factors that promote viral assembly, towards developing inhibitors to halt viral egress.

Associate Professor Vijaykrishna Dhanasekaran (Vijay)

BSc, MSc, MPhil (University of Madras) Microbiology, PhD (University of Hong Kong) Ecology and Evolution and Postdoctoral training (University of Hong Kong).  Head, Laboratory of Virus Evolution and Infectious Disease dynamics. Biomedicine Discovery Fellow. Adjunct Associate Professor Duke-NUS Medical School, Singapore, and visiting consultant, WHO Influenza Collaborating Center for Reference and Research on Influenza, Melbourne.

Email: vijay.dhanasekaran@monash.edu
Phone: +613 9905 5415
Web: https://virusevolution.monash.edu/
https://med.monash.edu.au/microbiology/staff/dhanasekaran-2.html
Twitter Handle: @vijay_lab

The overarching goal of my laboratory is studying the factors that shape the emergence, evolution, and incidence of rapidly evolving viral pathogens such as influenza with a focus on improving control and therapeutic strategies. We conduct disease surveillance in animals and humans, employ molecular virology, genomics and experimental evolution experiments, and use computational methods in evolutionary biology and epidemiology in our research. Our current research interests include the development of universal vaccination approaches against seasonal and pandemic influenza viruses by better understanding the impact of population level immunity on virus evolution.

Associate Professor Fasséli Coulibaly

BSc Hons (Paris-Sud) Biochemistry, MSc (ENSCM) Chemistry, PhD (Paris-Sud) Biochemistry, and Postdoctoral training (University of Auckland, New Zealand).
Head, structural virology laboratory at the Department of Biochemistry and Molecular Biology. Infection and Immunity program, Biomedicine Discovery Institute.

Email: fasseli.coulibaly@monash.edu
Phone: +613 9902 9225
Web: https://www.monash.edu/discovery-institute/coulibaly-lab

The overarching goal of my laboratory is to address long-standing questions in virus assembly, antigenicity and evolution using structural and molecular virology. We investigate human, animal and bacterial viruses. Our current research has a strong focus on insect-borne viruses, which have a profound impact on human activities through the diseases they cause, their role in the control of invertebrate populations and major biotechnological applications.

My laboratory focuses on understanding the biology of some of these viruses to inform the design of new vaccines and biotechnological tools. To this end, we integrate complementary structural biology approaches to generate detailed models of infectious particles and virus-induced assemblies that facilitate infection. Specifically, we aim to elucidate these complex structures in their near native state using innovative methodologies such as single particle cryo-electron microscopy, in vivo crystallisation and X-ray serial microcrystallography.